Tag: DCGI approves Phase II/III clinical trail of Covaxin in the age group of 2-18 years

[tdb_header_logo align_vert="content-vert-top" display="" align_horiz="content-horiz-center" show_title="none" show_tagline="none" tagline_align_horiz="content-horiz-left" tdc_css="eyJhbGwiOnsibWFyZ2luLWJvdHRvbSI6IjAiLCJkaXNwbGF5IjoiIn0sInBvcnRyYWl0Ijp7Im1hcmdpbi1ib3R0b20iOiIzMCIsImRpc3BsYXkiOiIifSwicG9ydHJhaXRfbWF4X3dpZHRoIjoxMDE4LCJwb3J0cmFpdF9taW5fd2lkdGgiOjc2OCwicGhvbmUiOnsibWFyZ2luLWJvdHRvbSI6IjI1IiwiZGlzcGxheSI6IiJ9LCJwaG9uZV9tYXhfd2lkdGgiOjc2N30=" media_size_image_height="179" media_size_image_width="259" image_width="60" image="1275"]